<SEC-DOCUMENT>0001564590-20-024870.txt : 20200513
<SEC-HEADER>0001564590-20-024870.hdr.sgml : 20200513
<ACCEPTANCE-DATETIME>20200513090904
ACCESSION NUMBER:		0001564590-20-024870
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200513
DATE AS OF CHANGE:		20200513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				462702363
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38792
		FILM NUMBER:		20871284

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>alec-8k_20200513.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-8k_20200513.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;"><a name="_Hlk16150588"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported)</p>
<p style="margin-top:7pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">May 13, 2020</p>
<p style="text-align:center;margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alector, Inc.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-38792</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">82-2933343</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation)</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">131 Oyster Point Blvd. Suite&#160;600 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, California 94080 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> <font style="letter-spacing:-0.1pt;font-weight:normal;">(Address of principal executive offices, including zip code)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(415) 231-5660 <br /><font style="letter-spacing:-0.1pt;font-weight:normal;">(Registrant&#8217;s telephone number, including area code)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not applicable</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Former name or former address, if changed since last report)</p>
<p style="margin-top:9pt;margin-bottom:5pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:3.04%;text-indent:-3.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:3.04%;text-indent:-3.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:3.04%;text-indent:-3.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.04%;text-indent:-3.04%;letter-spacing:0pt;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin-bottom:5pt;margin-top:5pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Exchange Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:33.49%;"></td>
<td style="width:26.29%;"></td>
<td style="width:40.11%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALEC</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC </p>
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The Nasdaq Global Select Market)</p></td>
</tr>
</table></div>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company &#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> </p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> </p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;"><a name="_Hlk16150604"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 2.02.&nbsp;&nbsp;Results of Operations and Financial Condition.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 13, 2020, Alector, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March 31, 2020. A press release announcing these results, which is attached hereto as Exhibit 99.1, is incorporated herein by reference.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:106.4%;">
<tr>
<td valign="top"  style="width:11.74%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.74%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:88.26%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alec-ex991_6.htm"><font style="text-decoration:underline;">Press Release dated May 13, 2020.</font></a></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALECTOR, INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 13, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arnon Rosenthal</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arnon Rosenthal, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co-founder and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>alec-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alec-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqec10vv2ehz000001.jpg" title="" alt="" style="width:153px;height:41px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1C262C;font-family:Arial;letter-spacing:-0.2pt;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#1C262C;font-family:Arial;letter-spacing:-0.2pt;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Alector Reports 2020 First Quarter <font style="color:#000000;">Financial Results and Business Highlights</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;color:#000000;font-size:11pt;font-family:Arial;">Provides business continuity update regarding COVID-19</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;color:#000000;font-size:11pt;font-family:Arial;">Continued execution across immuno-neurology platform</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;color:#000000;font-size:11pt;font-family:Arial;">On track to initiate pivotal Phase 3 trial of AL001 in patients with frontotemporal dementia with a progranulin mutation (FTD-GRN) and a Phase 2 study of AL002 in Alzheimer&#8217;s disease patients in 2020</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:18pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:center;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;color:#000000;font-size:11pt;font-family:Arial;">Strong cash and investments position of $548.5 million to support execution of clinical, research, and operational goals</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SOUTH SAN FRANCISCO, Calif.,<font style="font-weight:normal;">&#160;May 13, 2020&#160;--&#160;Alector, Inc.&#160;(Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and financial results for the first quarter ended&#160;March 31, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;At Alector we are committed to developing transformative treatments for neurodegeneration. We believe that our mission could benefit millions of patients and families affected by neurodegenerative diseases, and even with the current COVID-19 health crisis, we remain focused on advancing our portfolio of immuno-neurology programs,&#8221; said Arnon Rosenthal, Ph.D., Co-founder, and Chief Executive Officer of Alector. &#8220;Our COVID-19 task force and the entire Alector team continues to focus on initiating a pivotal Phase 3 study of AL001 in FTD-GRN patients and a Phase 2 study of AL002 in Alzheimer&#8217;s disease patients in 2020.&#8221;</p>
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Business Highlights</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 Response</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alector is actively monitoring the evolving impact of COVID-19 on its operations and clinical trials, with a primary focus on the health and safety of employees, clinical trial participants, and clinical trial site teams. The Company is complying with regulatory, institutional, and governmental guidance for conducting its business worldwide. As the COVID-19 pandemic continues to evolve, it could impact Alector&#8217;s programs in the future. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also continuing with its efforts to complete enrollment across ongoing clinical trials. Currently, certain clinical trial sites have delayed enrollment of new patients and paused clinical trial visits<font style="font-size:10pt;font-family:Calibri;"> </font>across clinical development programs. Alector is aware that some participants in ongoing trials have not been able to receive scheduled doses on time due to site closures or various state and local shelter-in-place directives. However, the Company is continuing to collect data from all existing clinical trial participants enrolled to date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>The Company remains on track with previously stated guidance to initiate a pivotal Phase 3 study of AL001 in FTD-GRN patients in 2020. Alector also intends to initiate a Phase 2 study of AL002 in Alzheimer&#8217;s disease patients in 2020. Ongoing activities for AL003, AL101, and AL014 </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqec10vv2ehz000001.jpg" title="" alt="" style="width:153px;height:41px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are continuing as planned. </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believes that its cash and investments as of March 31, 2020 will be sufficient to fund its anticipated operations through 2022</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Progranulin Portfolio: AL001, AL101 </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">The Company remains on track to advance AL001 into a pivotal Phase 3 study in FTD-GRN patients in 2020.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">Alector expects to present preliminary Phase 2 data of AL001 in FTD-GRN patients at medical meetings in 2020. The number of patients with available data for presentation may be impacted by the COVID-19 pandemic.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">Initial Phase 1a data of AL101 in healthy volunteers are also expected during in 2020. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Alzheimer&#8217;s Disease Portfolio: AL002, AL003, AL014</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">Following the completion of the Phase 1a study with AL002 and based on the safety and biomarker data collected in preclinical studies and in healthy volunteers, and in agreement with its partner AbbVie, Alector has closed enrollment for the Phase 1b study of AL002 and will proceed with initiating a Phase 2 trial in Alzheimer&#8217;s disease patients in 2020.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><a name="_Hlk39079102"></a><font style="font-family:Arial;">The Company continues to advance the Phase 1b trial <a name="_Hlk39079102"></a>of AL003 in Alzheimer&#8217;s disease. AL003 is being developed by Alector in collaboration with its partner AbbVie. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">Alector plans to initiate Phase 1 development for AL014 within the next 12 months. AL014 is the Company&#8217;s latest prioritized candidate that targets MS4A4A, a transmembrane receptor protein that is expressed selectively in microglia in the brain and is associated with control of microglia functionality and potential viability.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-oncology Portfolio</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:18pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:18pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Calibri;font-size:11pt;"><font style="font-family:Arial;">In March, Alector entered into a regional licensing agreement with Innovent Biologics for the development and commercialization of AL008 in oncology indications in China. AL008 is a potentially best-in-class SIRP-alpha inhibitor with a unique dual mechanism of action that non-competitively antagonizes the CD47-SIRP-alpha pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a "don't eat me signal") while also engaging Fc gamma receptors to promote immuno-stimulatory pathways that drive anti-tumor immunity. Alector retains the global rights for AL008 outside of China. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">First Quarter 2020 Financial Results</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Revenue.&#160;<font style="font-weight:normal;">Collaboration revenue for the quarter ended March 31, 2020 was&#160;$7.2 million&#160;compared to&#160;$5.6 million&#160;for the same period in 2019. This increase was primarily due to an increase in expenses for the AL002 and AL003 programs compared to the same period last year.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>R&amp;D Expenses.&#160;<font style="font-weight:normal;">Total research and development expenses for the quarter ended March 31, 2020 were&#160;$34.6 million&#160;compared to&#160;$20.6 million&#160;for the same period in 2019. This increase was driven by an increase in personnel-related expenses as headcount grew to support the advancement of the clinical and pre-clinical programs. Additionally, expenses increased due to timing of manufacturing runs and continued progression through clinical trials for several </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqec10vv2ehz000001.jpg" title="" alt="" style="width:153px;height:41px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">programs. </font><font style="font-weight:normal;">Expenses for AL</font><font style="font-weight:normal;">014</font><font style="font-weight:normal;"> increased as well as for other early stage programs as investment in research and clinical pipeline continues.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">G&amp;A Expenses.&#160;<font style="font-weight:normal;">Total general and administrative expenses for the quarter ended March 31, 2020 were&#160;$14.6 million&#160;compared to&#160;$5.8 million&#160;for the same period in 2019. This increase was primarily due to an</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;"> </font><font style="font-weight:normal;">increase in personnel-related expenses due to increased headcount to support the advancement of the clinical and pre-clinical programs and an increase in legal costs associated with our ongoing arbitration proceedings for certain intellectual property matters.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Net Loss.&#160;<font style="font-weight:normal;">For the quarter ended March 31, 2020,&#160;Alector&#160;reported a net loss of&#160;$40.0 million, compared to a net loss of&#160;$18.6 million&#160;for the same period in 2019. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk39079660"></a>Cash Position.<font style="font-weight:normal;"><a name="_Hlk39079660"></a>&#160;Cash, cash equivalents, and marketable securities were&#160;$548.5 million&#160;as of&#160;March 31, 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About&#160;Alector</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Alector&#160;is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.&#160;Alector&#160;is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain&#8217;s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company&#8217;s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer&#8217;s disease.&#160;Alector&#160;is headquartered in&#160;South&#160;San Francisco, California. For additional information, please visit&#160;www.alector.com.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offering, and other risks and uncertainties related to the offering,&#160;Alector&#160;and its business as set forth in Alector&#8217;s Annual Report on Form 10-K filed with the&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) on&#160;March 24, 2020, as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for&#160;Alector&#160;to differ materially from those contained in Alector&#8217;s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and&#160;Alector&#160;specifically disclaims any obligation to update any forward-looking statement, except as required by law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqec10vv2ehz000001.jpg" title="" alt="" style="width:153px;height:41px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Sele</font><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">cted Consolidated Balance Sheet Data </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:92.3%;">
<tr style="height:10.85pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="width:17.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
</tr>
<tr style="height:15.3pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr style="height:10.85pt;">
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:14.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and marketable securities</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548,535</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353,073</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">618,928</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421,913</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities (excluding deferred revenue)</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,686</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,805</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue (including current portion)</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146,230</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,401</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,194</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227,170</p></td>
</tr>
<tr style="height:16pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,734</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,743</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statement of Operations Data</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76.36%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,171</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,605</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,605</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,607</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,644</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,759</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,249</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,366</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42,078</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,761</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,059</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,201</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,019</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,560</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.53</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.42</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in computing net loss per share, basic and diluted</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,820,950</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,828,106</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Source: Alector, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gqec10vv2ehz000001.jpg" title="" alt="" style="width:153px;height:41px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Contacts</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media:<br />1AB<br />Dan Budwick, 973-271-6085<br />dan@1abmedia.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors:<br />Alector, Inc.<br />ir@alector.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gqec10vv2ehz000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gqec10vv2ehz000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &\!G<# 2(  A$! Q$!_\0
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M,#*FN:&J-FBBBO=. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117/^(M0**+.-L%AF0CT["N;&8J&%HNK+I^+-:-)U9J"-:Z2._LIH(Y4)
M88R#G!KF(] OVF"-&$7/+E@1BJVFO(FI6YB)W%P..X[UW5>-1A1SA>UJQ<7'
M31[]>QVSE/!^Y%W3*UE8PV$/EQ+R?O,>K59HHKWZ=.-.*A!62/.E)R=WN%%%
M8-YXD2*<QV\0E53@N6X/TK'$XNCAH\U5VN:4J,ZKM!&]156PO8[^V$R KSAE
M/8U:K:G4C4BIP=TS.47%\KW"BBBK$%%%% "$A02Q  Y)-9%QXBM(9-D:M-CJ
MR]*R-:U&:XNY8-Q6&-BH4=R.YK,1'D<(BEF/  &2:^6QV>5%4=/#K;K_ )(]
M6A@(\O-4-_6K_P"UZ7#);LPB=R)!W! Z&N>KK])TTP:<T-VBMYK;BAYQ_P#7
MJW#IMG;MNBMXPWJ1D_K55LJQ&.E&O4E9M*Z[?+\0ABZ=!.G%7LSD]/T^XNKF
M,I&P0,"7(P /K6OJF@RW-VT]NZ?/RRL<8/M6_17=1R2A"BZ4VW=WOL<\\=4<
M^>.AY[(ABE>-L91BIQ[5;L]*N;^%I(=F%;:0QP:@O/\ C]N/^NC?SKHO#'_'
ME-_UT_H*^:P&$IU\7[&>VOX'IXBK*G1YX[Z&-+HVH1<FV9A_L$-_*J3H\;;7
M5E;T88->A4R2*.9=LL:NOHPS7M5>'*;_ (4VO77_ ".*&92^U$X!'>-@R,RL
M.A4X-:]GXBN82%N!YR>O1A_C6G=>';6;+0DPM[<K^58%[I=U8G,J9C[.O(_^
MM7ESPN/RY\\7IW6J^:_S1U1JX?$KE>_F==9W]O?)NA?)'53P1^%6:\^CD>&0
M21N5=>A!KIM*UU;DK!=864\*_9O\#7M9?G<*[5.MI+\'_D<6(P,J?O0U1MT4
M45[QYX4444 %%%8=_P"(1;730PPA]APS$XY]!7/B<52PT>>J[(TI4IU7:"-R
MBJ>GZC%J$&]/E=>&0GD5<K6E5A5@IP=TR91<'RRW"N=UG1  UU:+C'+QC^8_
MPKHJ*PQ>$IXJGR5%Z/L71K2I2YHGG@)4@@D$<@BNNT74_MT'ERG]_&.?]H>M
M96O:8+:3[3"N(G/S ?PG_ UEVMS):7*3QGYE/Y^U?(X>K5RO%.$]NOFNZ_KR
M/8J0ABJ5X[G?45';SI<VZ31G*N,BI*^WC)22DMF>&TT[,****8@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\0?PKV#2M8T[7+%;W3+R&ZMVZ/$V<'T(Z@^QYK*47'<UC-2V+M%%%24%%%%
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M.TDSZ_HHHKD.T**** "BBB@ HHHH **** "BBB@ KYR^/O\ R/=C_P!@R/\
M]&RU]&U\Y?'W_D>['_L&1_\ HV6M*7Q&5;X3RNNX^#__ "5/1O\ MO\ ^B)*
MX>NX^#__ "5/1O\ MO\ ^B)*Z)?"SGA\2/JFBBBN,[0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /E;XP?\E3UG_MA_Z(CKAZ[CXP?\E3UG_MA_
MZ(CKAZ[(_"CBG\3+%G8WFH2F*RM)[F0+N*0QER!TS@=N1^=7?^$8U_\ Z >I
M_P#@))_A7?\ P"_Y'N^_[!DG_HV*OHVLYU.5V-(4E)7/C/\ X1C7_P#H!ZG_
M . DG^%'_",:_P#] /4__ 23_"OLRBI]L^Q7L%W/C/\ X1C7_P#H!ZG_ . D
MG^%'_",:_P#] /4__ 23_"OLRBCVS[![!=SXS_X1C7_^@'J?_@))_A1_PC&O
M_P#0#U/_ ,!)/\*^S**/;/L'L%W/C/\ X1C7_P#H!ZG_ . DG^%'_",:_P#]
M /4__ 23_"OLRBCVS[![!=SXS_X1C7_^@'J?_@))_A1_PC&O_P#0#U/_ ,!)
M/\*^S**/;/L'L%W/C/\ X1C7_P#H!ZG_ . DG^%'_",:_P#] /4__ 23_"OL
MRBCVS[![!=SXS_X1C7_^@'J?_@))_A1_PC&O_P#0#U/_ ,!)/\*^S**/;/L'
ML%W/ESP/\,M:\0:Y;_;].N;/3(G#7$MQ&8]RC^%0>23T]J^HZ**SE-R-(044
M%%%%26%%%% !7DWQ&^+\.AO-I'A]DGU)<I-<D;HX#W _O,/R'?/(J#XN_$N3
M2 _AS1)MM\Z_Z7<(>85/\"GLQ'4]@?4\?/U;4Z=]685*EM$6+Z_N]3O)+R^N
M9;BXE.7DE8LQJO16EHF@:KXBOA9Z392W4QZA!PH]68\*/<FM]CGW,VBO<O#O
MP!7:LWB/4R3U-M9=!]78?R'XUZ-I?PY\(:0JBVT&T=A_'<)YS9]<OG'X5FZL
M4:JC)GR5'%),VV*-W;KA5R:O1Z!K,I(CTB_<CDA;9S_2OLR&"&WC\N")(D'1
M44*/R%25'MO(OV'F?%DFBZK#N\W3+U-OWMUNPQ]>*I,K(Q5U*L.H(P17W!4%
MU96E['Y=W:PW"?W98PP_(T_;>0>P\SXEHKZNU?X5>#M81M^D1VDAZ269\HC\
M!\OYBO+?%'P*U33TDN= NAJ,*Y/V>0!)@/;^%OT]A5*I%F<J4D>1UI:)K^J>
M'-06]TF\EMIAUVGY7'HPZ,/8U2N+:>SN)+>YADAGC;:\<BE64^A!Z5%6FYGL
M?3GP^^*UAXMV:??JEEK&.$S^[G_W">_^R?PS7HM?$$<CPRI+$[)(C!E93@J1
MT(/K7TA\*OB7_P )1 -&U9U&KPIE).GVE1U/^\.X[]?7&%2G;5'33J7T9Z?1
M116)L%>6?&+P#>>)[6VU;28O.O[1#') /O2QYR-ON#GCOD]^#ZG13BVG="E%
M25F?&A\+^(%)!T+4P1P0;23_  I/^$8U_P#Z >I_^ DG^%?9E%:^V?8Q]@NY
M\9_\(QK_ /T ]3_\!)/\*/\ A&-?_P"@'J?_ ("2?X5]F44>V?8/8+N?&?\
MPC&O_P#0#U/_ ,!)/\*/^$8U_P#Z >I_^ DG^%?9E%'MGV#V"[GQG_PC&O\
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MQK__ $ ]3_\  23_  KTKX1_#G56\1P:]J]E-:6EGEX4G0H\LG0?*><#KGU
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MC8X2=/FC?Z,.,^QYK2,T]C*4)1W,&O1/ OQ9U;PJ\=G?M)J&DC \IVS)"/\
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M?27]D7E \Q&VDCO[UHUTY92I4\+%4G=/4RQ4Y2JOGW"BBBN\YPHHHH ****
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M;7/5^(Z*/PA11169J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5ROQ!\71^#?"T]\NUKR4^3:1GO(>Y'H!DGZ8[UU5?+_QA\3GQ!XUEM89-UEI
MN;>( \%_^6C?F,?115PCS,BI+EB<%<3RW5Q+<3R-)-*Y>1V.2S$Y)-1T5N>$
M/#-SXM\26NDVQ*B0[II<9\N,?>;^@]R!75L<:U9M?#WX=7OC:^,CE[;286Q/
M<XY8_P!Q/5O?H/R!^F=$T'3/#NG)8:5:1V\"]0HY8^K'J3[FIM*TNST72[?3
M;"$16MNFQ$'\SZDGDGU-7*Y9S<F=D(**"BBBH+"BBB@ HHHH **** .4\:>
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M"Y*D'*L!T-6Z*BI3C4@X35TRHR<7S+<YNVTRUT^]1[N]BW(0RITY[$UT8(8
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M_MO_ .B)*Z)?"SGA\2/JFBBBN,[0HHHH **** "BBB@ HHHH **** "BBB@
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M[G_:*C=^N:SK+9FM![HUJ***Q-PHHHH *HZU_P @'4?^O:3_ -!-7JHZU_R
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MC'_ JTJ*\3*F[2/INBBBN4[ HHHH **** "BBB@ HHHH *^<OC[_ ,CW8_\
M8,C_ /1LM?1M?.7Q]_Y'NQ_[!D?_ *-EK2E\1E6^$\KKN/@__P E3T;_ +;_
M /HB2N'KN/@__P E3T;_ +;_ /HB2NB7PLYX?$CZIHHHKC.T**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#Y6^,'_)4]9_[8?^B(ZX>NX^,'_)4]
M9_[8?^B(ZX>NR/PHXI_$SU3X!?\ (]WW_8,D_P#1L5?1M?.7P"_Y'N^_[!DG
M_HV*OHVN>K\1T4?A"BBBLS4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MH,.[[TLS;?7 09_7]:\(KJI?"<E7XA\4;32I$@RSL%4>YK[8M+9+.S@M8_\
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M10 4444 %%%% !7P]7W#7P]6]'J<]?H%?1OP"_Y$2^_["<G_ **BKYRKZ-^
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M^2@Z!_U_1?\ H0KZ^KY!\ ?\E!T#_K^B_P#0A7U]6=;<VH;,****Q-@HHHH
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MG$/_ %\R_P Q7HU><_!#_DG$/_7S+_,5Z-7)/XF=L/A04445)04444 %%%%
M!1110 4444 %-DD2&)Y9'"1HI9F8X  ZDTZO,?C3XN71/#!T:WD'V[4U*$ \
MI#_$?Q^[^)]*<5=V%)V5SP'Q-K#:_P")M2U5LXNKAG0'J$S\H_ 8%95%%=AP
MO4]B_9^TPRZYJVJLORP6ZP*3ZNV3^B?K17H7P@T Z'X M9)$VW%^QNWSUPP
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M&QWX_P ]*YH$J00<$'(-)17%C,7+%5%4DK.VMC>C15*/*GH=Y97*WEG'.O\
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M?1OP"_Y$2^_["<G_ **BJJOPDT?B/5****YCJ"BBB@ JCK7_ " =1_Z]I/\
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M/JFBBBN,[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E;XP?\
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M5>+U]6_"G1?[$^'FFHRXFNU-W+[E^5_\=VC\*JJ[1)I*\CM****YCJ"BBB@
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M_P#)4]&_[;_^B)*Z)?"SGA\2/JFBBBN,[0HHHH **** "BBB@ HHHH ****
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M?_;U_P"TJ\/KW#]HC_F6_P#MZ_\ :5>'UU4_A1R5?C9N>"_^1[\/?]A.V_\
M1JU]BU\=>"_^1[\/?]A.V_\ 1JU]BUG6W1I0V84445B;A1110 4444 %%%%
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M1117VAXAQVN6AMM2=@/DE^=?KW_6F:1J'V"\W/GRG^5_;W_"NHU*P34+4QG
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MV-J*LKA11161L%%%% !1110 4444 >3_ !ZT7[9X4L]61<O83[7..D<F ?\
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M:1-DB%\Q.?XXSRK?EC\<UBUUK4XFK'UM\.O%2^+?"%K>.X-Y$/)NAW\Q>_\
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M+5=))6L%5=2B$VFW"'^X2/J.1_*K517)Q:S$]D/\J]2M%2IRB]FF<D&U)-'
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M?:]%065W%?V%O>0'=#<1++&?56 (_0U/7&=P4444 %%%% !7SE\??^1[L?\
ML&1_^C9:^C:^<OC[_P CW8_]@R/_ -&RUI2^(RK?">5UW'P?_P"2IZ-_VW_]
M$25P]=Q\'_\ DJ>C?]M__1$E=$OA9SP^)'U31117&=H4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'RM\8/^2IZS_P!L/_1$=</7<?&#_DJ>L_\
M;#_T1'7#UV1^%'%/XF>J? +_ )'N^_[!DG_HV*OHVOG+X!?\CW??]@R3_P!&
MQ5]&USU?B.BC\(4445F:A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?-?QV_P"2@Q_]>,?_ *$]>95Z;\=O^2@Q_P#7C'_Z$]>95UP^%''4^)GH
MWP0_Y*/#_P!>TO\ (5]-U\R?!#_DH\/_ %[2_P A7TW6-7XC>C\(4445D:A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '@_P"T+_Q_Z#_URF_FE>+5[3^T+_Q_Z#_URF_FE>+5U4_A1QU?C9T?@#_D
MH.@?]?T7_H0KZ^KY!\ ?\E!T#_K^B_\ 0A7U]6=;<VH;,****Q-@HHHH ***
M* "BBB@ HHHH \._:(_YEO\ [>O_ &E7A]>X?M$?\RW_ -O7_M*O#ZZJ?PHY
M*OQLW/!?_(]^'O\ L)VW_HU:^Q:^.O!?_(]^'O\ L)VW_HU:^Q:SK;HTH;,*
M***Q-PHHHH **** "BBB@ HHHH **** "OAZON&OAZMZ/4YZ_0*^C?@%_P B
M)??]A.3_ -%15\Y5]&_ +_D1+[_L)R?^BHJJK\)-'XCU2BBBN8Z@HHHH *HZ
MU_R =1_Z]I/_ $$U>JCK7_(!U'_KVD_]!-"!GQ91117:<!]-_!#_ ))Q#_U\
MR_S%>C5YS\$/^2<0_P#7S+_,5Z-7)/XF=L/A04445)04444 %%%% 'D_QR\*
M#4] B\06T>;K3_EFP.6A)_\ 93S]"U?.U?;MQ;Q7=M+;7$:R0S(8Y$;HRD8(
M/X5\@^,_#4OA/Q3>:3(6:-&WP2$??C/*G^A]P:Z*4M+'-6C9W,"OJ_X9>*QX
MK\'V\TLFZ_M0(+H$\E@.&_X$,'ZY]*^4*[OX3^+!X7\81K<2;-/OP(+C)X4Y
M^1_P/'T8U52-T33ERR/J:BBBN4ZPHHHH **** "J>IV/V^R:$,%<'<I/3-7*
M*SJTXU8.G/9E0DX24ENCE[+P_="[1I]J1HP)PV2<>E=17*:MJUU]ODBBE:*.
M,[0%X)]ZU-"U)[V%XYFW2Q\Y]17B9;7P=&M+"T4[WW?6QW8FG6G!59V->BBB
MO?//,_6;1[S3V2,9D4AE'KBN9M-,NYKI$\B1 &^9F4@ 5U]W=165NTTQ(4=A
MU)]!5"SU^WN[A82CQLQPI;H3Z5X6883!UL3%U9VEV[_Y'?AZU:%)\D;HUJ**
M*]TX#D_$D>S45?L\8/XCBF>'I?+U55_YZ*5_K_2M[5M,_M&)-C!)4)VD]#GM
M532M">TNA<7#H67[JIGK[U\O5R_$+,E5A'W;IW_,]6.)IO#<DGK:QN4445]0
M>4%%->1(D+R.J*.I8X%0?VA9?\_=O_W\'^-1*I"+M)I%*,GLBS13(YHI?]7(
MC_[K T^J335T)IK<****8@HHHH X&\_X_;C_ *Z-_.NB\,?\>4W_ %T_H*YV
M\_X_;C_KHW\ZZ+PQ_P >4W_73^@KXO*/^1A]Y[>,_P!W^XW****^T/$"BBB@
M HI"0!DG J%KVT0X:ZA4^AD%3*<8_$[#46]B>BJXO[-NEW <_P#305.K*XRK
M!AZ@THU(3^%W!Q:W0M4M6E\G2KAO5-H_'C^M7:Y[Q-=#;%:J><[V_I_6N3,:
MZHX6<_*R]7H;8:GSU8HYRNZTV/RM-MT/7RP3^/-<7:0&ZNXH1_&P!^G>N^
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M%M?^A<F_\"Q_\31_PT+:_P#0N3?^!8_^)KP>BCV<0]K/N>\?\-"VO_0N3?\
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M "BBB@ HHJ&XN[:T4-<W$4*G@&1PH/YT 345%!<V]TF^WGCF3INC<,/TJ6@
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MO^0#J/\ U[2?^@FA SXLHHHKM. ^F_@A_P DXA_Z^9?YBO1J\Y^"'_).(?\
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M&U[Q+INE*#_I5PL;$=0N?F/X#)_"LJO5_@-HWVSQ9=ZJZYCL+?:I])),@?\
MCH?\ZWD[*YA%7DD?1*(L:*B*%51@ #@"EHHKC.T**** "BBB@ HHHH ****
M"BBB@ HHHH *\R^.6B_VCX'74$3,NG3K(3_TS;Y6_4J?PKTVJ6L:;%K&BWNF
MS?ZNZ@>%CZ;@1G\.M.+L[DR5U8^*Z*EN;>6SNYK:=2DT+M&ZGLP."/SJ*NPX
MC[#\%ZU_PD/@W2M3+;I)H )23_RT7Y7_ /'@:WJ\<^ &M>?HVIZ+(WS6THGB
M!_NN,$#V!7/_  *O8ZY)JTK';!WBF%%%%24%?.7Q]_Y'NQ_[!D?_ *-EKZ-K
MYR^/O_(]V/\ V#(__1LM:4OB,JWPGE==Q\'_ /DJ>C?]M_\ T1)7#UW'P?\
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MHM-2Q\]G,PR3_L'^(?3GU KFG3:U1U0J*6CW.SHHHK,U"BBB@ HHHH ****
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ME^9U-%%%?;GA!1110 4444 %%%% ')_$K6_[!\ :K<JQ6:6+[/$1UW/\N1]
M2?PKY*KW3]H/4Y%@T72E)$;M)<2#L2,*O_H35X77325HG+6=Y6"OIOX*:+_9
M?@&*Z=<3:A*TYSUVCY5'TPN?^!5\UV5I+J%_;V4 W37$JQ1CU9B /U-?:.G6
M,6F:9:V$ Q#;0I"GT4 #^5*L]+#HK6Y9HHHKG.D**** "BBB@ HHHH ****
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M[61[]_PT'I7_ $ [S_OZM'_#0>E?] .\_P"_JUX#11[*(>UD>_?\-!Z5_P!
M.\_[^K1_PT'I7_0#O/\ OZM> T4>RB'M9'OW_#0>E?\ 0#O/^_JT?\-!Z5_T
M [S_ +^K7@-%'LHA[61]2>$?BSH'BS4%TY$GLKY_]7'< 8D[X5@>OL<>U=[7
MQ):W4UE>0W=NYCG@D62-QU5@<@_G7VO!)YUO'+C&] V/3(K&I!1V-J4W):DE
M%%%9FH4444 >?_$WX<Q>,K 7ED$CUFW3$3' $R_W&/\ (]L^]?,EW:7%A=RV
MEW"\-Q"Q22-QAE([&OMNN,\=?#C2O&L'FO\ Z+J:+B.[1>3Z*X_B'ZCM6L*E
MM&8U*?-JCY1I58JP920P.01VK>\3^#-;\(W?DZK:,L9.([B/YHI/HWK['!]J
MP*Z$[G,TUN=[X>^+_BO046%[I-1MEX$=X"S >S@AOS)'M7HVE_'_ $:<*NJ:
M5>6CGJT#+*OZ[3^AKY\HJ73BRU4DCZJM/BYX(NP,:T(F/\,T$BX_';C]:TD^
M(7A!T##Q'IP!_O3@'\C7R'14>Q1?MI'UXWQ!\((I8^(].P/2<$_D*S[OXM>"
M+13G6TE8=%AAD?/XA<?K7RG11[%![:1]!ZM\?M&@5ETK2KN[D' :=A$GUXW$
M_D*\O\4?%#Q-XI5X)[L6EDW!MK3**P]&.<M]"<>U<915J$41*I)A117HG@SX
M1:YXE:.ZOD?3--/S>9*O[R0?["G^9P/K3;2W)2;=D<CX=\-ZGXIU6/3M+MS+
M*W+L>$C7NS'L/\C)KZG\%>#+#P5HHLK3]Y/)AKFY88:5OZ*.P[?4DU=\.>&-
M)\*Z:+'2;811]7<\O*?5F[G^7;%:]<\ZG-H=5.GRZO<****S- HHHH ****
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MJ=/E]0HHHK,T"BBB@ HHHH *HZU_R =1_P"O:3_T$U>JCK7_ " =1_Z]I/\
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M#D^N0*]THHI2DY.[*C%15D%%%%24%%%% !1110 4444 %%%% !1110 4444
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M'MF'L%W/D'_A /%W_0MZG_X#M1_P@'B[_H6]3_\  =J^OJ*/;,/8+N?(/_"
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M_P!"WJ?_ (#M1_P@'B[_ *%O4_\ P':OKZBCVS#V"[GR#_P@'B[_ *%O4_\
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M% !1110 4444 %%%% '.>-O"5MXR\.3:9,1',/WEM,1_JY!T/T/0^QKYFO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
